FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine

dc.creatorSousa, Clarisa B. Palatnik de
dc.creatorBarbosa, André de Figueiredo
dc.creatorOliveira, Sandra Maria
dc.creatorNico, Dirlei
dc.creatorBernardo, Robson Ronney
dc.creatorSantos, Wania R.
dc.creatorRodrigues, Mauricio M.
dc.creatorSoares, Irene
dc.creatorBorja-Cabrera, Gulnara P.
dc.date2019-02-28T14:38:20Z
dc.date2019-02-28T14:38:20Z
dc.date2008
dc.date.accessioned2023-09-27T00:13:32Z
dc.date.available2023-09-27T00:13:32Z
dc.identifierSOUZA, Clarisa B. Palatink de.; etal. FML vaccine against canine vsceral leishmaniasis: from second-generation to synthetic vaccine. Expert Review of Vaccines, v.7, n.6, p.833-851, 2008.
dc.identifier1476-0584
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/31929
dc.identifier10.1586/14760584.7.6.833
dc.identifier1744-8395
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8898700
dc.descriptionThe Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I-III) vaccine trials against canine visceral leishmaniasis (92-95% of protection and 76-80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune vaccine for canine prophylaxis in Brazil. The immune response raised by the vaccine is long lasting, immunotherapeutic and reduces dog infectivity blocking the transmission of the disease, as revealed by an in vivo assay. The preliminary epidemiological control data of vaccinated areas in Brazil indicate that, in spite of the still low vaccine coverage, there was a significant decrease in the incidence of the human and canine disease. A 36-kDa glycoprotein, in the FML complex, is the human marker of the disease, which was protective in mice as native recombinant protein or DNA vaccine. The DNA vaccine is now being tested against the canine disease. This review resumes the development of the second-generation FML-saponin-Leishmune vaccine, its adjuvant and of the NH36 DNA vaccine, toward the identification of its major epitopes that might be included in a possible future synthetic vaccine.
dc.description2022-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherTaylor & Francis
dc.rightsrestricted access
dc.subjectLeishmania infantum
dc.subjectLeishmania donovani
dc.subjectLeishmaniose visceral humana
dc.subjectLeishmaniose visceral humana
dc.subjectSaponinas
dc.subjectVacina de DNA
dc.subjectAntígeno FML
dc.subjectVacina de segunda geração
dc.subjectNucleosídeo hidrolase
dc.subjectCanine visceral leishmaniasis
dc.subjectCP05 saponin
dc.subjectDNA vaccine
dc.subjectFML antigen
dc.subjectHuman visceral leishmaniasis
dc.subjectLeishmania chagasi
dc.subjectLeishmania donovani
dc.subjectNucleoside hydrolase
dc.subjectQS21 saponin
dc.subjectSecond-generation vaccine
dc.titleFML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine
dc.typeArticle


Este ítem pertenece a la siguiente institución